Nanotech moves from discovery to commercialization with $50B 2006 sales

For two decades, the term "nanotechnology" has been primarily associated with an R&D race spanning the public and private sectors. But nanotech is now shifting from discovery to commercialization, with $50.0 billion in nano-enabled products sold worldwide last year from pharmaceuticals to power tools - creating sustained competitive advantage for companies as diverse as US drug major Abbott Laboratories and engineering conglomerate Black & Decker. This transition - and a path for businesses and investors to harness it - is the focus of Lux Research's new reference guide The Nanotech Report, 5th Edition.

"Business and financial leaders have relied on The Nanotech Report to inform their strategic decisions since 2001," said Michael Holman, head of Lux Research's Nanomaterials Intelligence service. "As nanotechnology moves from the lab to the marketplace, we've overhauled The Nanotech Report end-to-end - and introduced new sections on the commoditizing nanomaterials market, public equity investing in nanotech, and nanotech for energy and environmental application," he added.

Report aims to help in superior strategic decision-making